---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-001896"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:15:36.434670+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc

## Summary
- Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).
- Cash and equivalents $57.5M at March 31, 2022, down from $61.2M at Dec 31, 2021.
- Completed enrollment in Phase 2 liver fibrosis study; interim PSC readout expected late 2022; SSc Phase 2 launch planned by year-end.
- Appointed Jack Lawler as VP of Global Clinical Development Operations.
- Presented CCL24 data at SSc congress; findings support CM-101's role in fibrosis and endothelial damage.

## SEC filing metadata
- accession: 0001178913-22-001896
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/0001178913-22-001896-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-001896
- JSON: https://secwatch.observer/filing/0001178913-22-001896.json
- Plain text: https://secwatch.observer/filing/0001178913-22-001896.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.